about
sameAs
Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the ratPoly[N-(2-hydroxypropyl)methacrylamide] polymers diffuse in brain extracellular space with same tortuosity as small molecules.Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivoDifferences in the intracellular fate of free and polymer-bound doxorubicin.Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data.Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation.Poly[N-(2-hydroxypropyl)methacrylamide]-based tissue-embedding medium compatible with MALDI mass spectrometry imaging experiments.Polymer carriers for anticancer drugs targeted to EGF receptor.Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectinsDrug-HPMA-HuIg conjugates effective against human solid cancer.Polymeric anticancer drugs with pH-controlled activation.Induction of systemic antitumour resistance with targeted polymers.Noninvasive optical imaging of nanomedicine biodistribution.Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.Photodynamic therapy and imaging based on tumor-targeted nanoprobe, polymer-conjugated zinc protoporphyrin.Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes.Structural and chemical aspects of HPMA copolymers as drug carriers.Adenovirus-derived vectors for prostate cancer gene therapy.Clinical adenoviral gene therapy for prostate cancer.Polymer coatings for delivery of nucleic acid therapeutics.HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility.Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma.HPMA Copolymer-Drug Conjugates with Controlled Tumor-Specific Drug Release.Comparison of the pharmacological and biological properties of HPMA copolymer-pirarubicin conjugates: A single-chain copolymer conjugate and its biodegradable tandem-diblock copolymer conjugate.Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies.Thermoresponsive Polymer Micelles as Potential Nanosized Cancerostatics.Synthesis and Properties of Star HPMA Copolymer Nanocarriers Synthesised by RAFT Polymerisation Designed for Selective Anticancer Drug Delivery and Imaging.Comparison between linear and star-like HPMA conjugated pirarubicin (THP) in pharmacokinetics and antitumor activity in tumor bearing mice.Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro.Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage.HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death.HPMA copolymer conjugates of DOX and mitomycin C for combination therapy: physicochemical characterization, cytotoxic effects, combination index analysis, and anti-tumor efficacy.Fine tuning of the pH-dependent drug release rate from polyHPMA-ellipticinium conjugates.Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution.Polymer therapeutics with a coiled coil motif targeted against murine bcl1 leukemia.Micelles of zinc protoporphyrin conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer for imaging and light-induced antitumor effects in vivo.HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release: synthesis and characterization of distribution and tumor accumulation in mice by noninvasive multispectral optical imaging.Overcoming cellular multidrug resistance using classical nanomedicine formulations.
P50
Q28325177-A57CDFEC-66B4-434D-B750-857A9743414FQ28346261-FAE753AD-9396-467A-8494-11F4F85FCEDDQ28539158-D0312B37-2C30-4774-ABE7-BBEA137A1A46Q30729281-403819A4-6199-4390-A0B5-CBF949520861Q33188242-024D6437-5448-461B-B670-08C3300DF2A6Q33635000-42B8A24A-8CFD-48E6-A863-C00F174C1AB1Q33920041-F2D974D5-2393-4979-89DF-FB5F1C809AD1Q34450114-E490C19B-3D52-4741-B7E7-1615F4D7BAD9Q34765825-52EC2F28-4718-41AE-AA57-F719DD4AA97FQ35098585-2ED78E42-433E-482E-9817-4B7355A78768Q35739335-1683559D-8A3D-4012-95D6-9C4A77E8A63EQ36161514-31B6F24A-BC9C-4D37-BA8A-39FD425F31C0Q37095731-FE90A918-0FF6-47E8-9F3B-58E541DD05DDQ37116929-DF241316-97CC-4E2C-BB6A-679CEA7669CFQ37474448-A3B98E25-8D93-4EF1-B9CC-609D78C13F1CQ37627094-F4C0BAF0-1508-4D22-8713-33D4085C6739Q37636753-495E6E14-2662-4BCF-A977-99C738EA1666Q37641338-3B5CA467-6047-40CC-BA9C-24D56CA69D4FQ37641338-977F841C-A07F-47A8-A705-D6501063DDAEQ37650343-2CE249BB-568D-4E65-8145-70DB9C29113CQ37650343-7140550C-8B76-4543-BCA1-47D90DAE45AFQ37988294-D11E0811-A2B9-439B-8371-3A87699B77CBQ38551625-41835FA8-D74C-469A-AB5A-68D7503F944FQ38569655-D3726821-79B9-4823-BEBF-24662A2B9E54Q38626421-BBCCB99B-3F91-4186-BCB2-B58821669848Q38772869-72A5873C-E3C0-43A5-A9B6-6512B1885775Q38816325-B08F6999-1F00-474C-BD75-E0E7F8707AA9Q38855472-9D48B43F-03D9-46CC-8B00-7BB93DB9128DQ38904632-912A6E8F-CAD8-4A50-9833-EEEFC80DF72CQ38933698-9FF57FF4-DA06-428F-9721-E2A9FFF794BEQ38979689-3D416992-FF14-4BBE-9D7D-0610AD3B42DFQ39015134-45A24F04-3376-41FA-88F1-D20AA61CCE22Q39056643-3493839D-9DB0-4631-8F6B-117B8B18774CQ39089349-07709DA8-7080-41F9-B8E7-4BB0AFBF663EQ39096548-0D0E447A-B79D-4145-9863-9C9B54EA4290Q39110784-1863917B-C4F4-4DFA-8928-8FDF6C8D60F3Q39148673-6BC871C1-F0B9-4F9A-9829-B323F0FAE36AQ39200977-D3D9CA04-1F02-4CC9-A9A3-15DE0DB64193Q39230819-B00784A5-9CF3-42CF-9B3D-20993EA0FCFFQ39320481-1802D632-F3A4-4B7B-A67D-3163095CFE80
P50
description
Czech chemist
@en
Czech chemist
@en-ca
Czech chemist
@en-gb
Tšehhi keemik
@et
chimist ceh
@ro
chimiste tchèque
@fr
kimist çek
@sq
químic txec
@ca
químico checo
@es
químico checo
@gl
name
Karel Ulbrich
@ast
Karel Ulbrich
@cs
Karel Ulbrich
@en
Karel Ulbrich
@es
Karel Ulbrich
@fr
Karel Ulbrich
@nl
Karel Ulbrich
@sk
Karel Ulbrich
@sl
type
label
Karel Ulbrich
@ast
Karel Ulbrich
@cs
Karel Ulbrich
@en
Karel Ulbrich
@es
Karel Ulbrich
@fr
Karel Ulbrich
@nl
Karel Ulbrich
@sk
Karel Ulbrich
@sl
prefLabel
Karel Ulbrich
@ast
Karel Ulbrich
@cs
Karel Ulbrich
@en
Karel Ulbrich
@es
Karel Ulbrich
@fr
Karel Ulbrich
@nl
Karel Ulbrich
@sk
Karel Ulbrich
@sl
P214
P106
P1412
P19
P21
P214
P31
P496
0000-0003-2174-9654
P569
1947-01-01T00:00:00Z
1947-02-27T00:00:00Z
P570
2019-06-19T00:00:00Z
P691
jo2004259877
P734
P735
P7859
viaf-84168808